Dr. Liu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
560 1st Ave. TH4-12A
New York, NY 10016Phone+1 212-263-2269
Summary
- Dr. Cheng Z. Liu is a pathologist in New York, NY at NYU Langone Hospitals. He received his medical degree from Hubei Medical University and has been in practice 25 years. He specializes in anatomic pathology and clinical pathology.
Education & Training
The MetroHealth System/Case Western Reserve UniversityResidency, Pathology-Anatomic and Clinical, 1996 - 2000
Northwestern university Ph.D., Cell and Molecular Pathology , 1990 - 1995
Hubei Medical UniversityClass of 1982
Certifications & Licensure
NY State Medical License 2014 - 2025
OK State Medical License 2001 - 2025
WI State Medical License 2013 - 2025- American Board of Pathology Anatomic Pathology & Clinical Pathology
Publications & Presentations
PubMed
- Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) (Milan IVB) and Its Subgroups: A Multi-Institutional Analysis of Risk of Neoplasm and Malignancy.Rong Xia, Issa Hindi, Deepika Savant, Samer Khader, Sigfred Lajara
Diagnostic Cytopathology. 2024-12-01 - 5 citationsMolecular Profiles of Noninvasive, Minimally Invasive, and Invasive Follicular Patterned Thyroid Neoplasms with Papillary Nuclear Features.Tamar C Brandler, Fang Zhou, Cheng Z Liu, Antonio Serrano, Wei Sun
Thyroid. 2023-06-01 - 1 citationsCase Report: Giant Thyroid Angiolipoma-Challenging Clinical Diagnosis and Novel Genetic Alterations.Reid Wilkins, Elcin Zan, Olga Leonardi, Kepal N Patel, Adam S Jacobson
Head and Neck Pathology. 2023-03-01
Press Mentions
Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple MyelomaSeptember 28th, 2022- Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver CancerAugust 3rd, 2022
- Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80June 6th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
